How J, Lee P S, Seet L C, Tan P K
Diving Medical Centre, Republic of Singapore Navy, Ministry of Defence.
Aviat Space Environ Med. 1988 Jul;59(7):646-50.
Most clinical trials investigating prevention of seasickness with transdermal scopolamine have been short-term, and little information regarding long-term use is available. We report here a double-blind trial conducted on board a flat-bottomed Republic of Singapore Navy vessel of 2,490 tons, sailing in the South China Sea. The trip lasted 26 d, but self-assessment by the 122 adult male participants (using a simplified scale quantifying the level of seasickness) was confined to the 18 d spent at sea. We found that the protection rate with transdermal scopolamine was 46-57%, with maximum benefits to inexperienced participants, during the early preadaptation phase, or in rough seas even after adaptation. Unwanted effects were few and generally minor. We concluded that the benefits of Scopoderm were worth exploiting even for long trips in moderate-to-rough seas.
大多数关于使用东莨菪碱透皮贴剂预防晕船的临床试验都是短期的，关于长期使用的信息很少。我们在此报告一项在一艘2490吨的新加坡共和国海军平底船上进行的双盲试验，该船在中国南海航行。航程持续26天，但122名成年男性参与者的自我评估（使用一个简化的量表来量化晕船程度）仅限于在海上度过的18天。我们发现，东莨菪碱透皮贴剂的保护率为46%-57%，对没有经验的参与者、在早期预适应阶段或即使在适应后处于波涛汹涌的海面时，益处最大。不良反应很少，而且一般较轻。我们得出结论，即使是在中度至波涛汹涌的海面进行长途旅行，东莨菪碱贴剂的益处也值得利用。
